Combination treatment with antiEGFR monoclonal antibodies in advanced nasopharyngeal carcinoma : a meta-analysis.

Abstract

PURPOSE:

The objective of this study was to compare the efficacy of the conventional treatment (radiotherapy/RT and chemotherapy/CT) and the combination treatment with antiepidermal growth factor receptor (anti EGFR) monoclonal antibodies in patients with primary nasopharyngeal cancer (NPC) using meta-analysis of data retrieved from the literature.

METHODS:

Seven databases (Pubmed, Embase, Cochrane Library, CBM, CNKI, Wanfang,VIP) were searched. Of 537 identified articles, 12 satisfied our eligibility criteria and entered this meta-analysis. A total of 821 patients in 12 randomized controlled clinical trials (RCTs) were included in the study to compare the effect in the short-term and long-term treatment.

RESULTS:

The combination treatment improved the objective complete remission rate (CR) of primary NPC and the metastatic lymph nodes, and the 1-year distant metastasis-free survival (MFS) rate relative risk (RR=1.40, 95%CI:1.29-1.53, p=0.00; RR=1.29, 95%CI:1.18-1.42, p=0.00; RR%1.17, 95%CI:1.01-1.35, p=0.03, respectively). There was no difference in the 2- and 3-year MFS rate (RR=1.06, 95%CI:0.85-1.33, p=0.60 ; RR=0.87, 95%CI:0.63-1.22) p=0.43, respectively).

CONCLUSION:

The combination with anti EGFR monoclonal antibodies and conventional treatment (RT and/or CT) improved the short-term therapeutic effect, but this benefit disappeared after 1 year.

• Authors: Cheng Yuan, Xin-Hua Xu, Zhuo Chen
• Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology (J BUON) 2015 Nov-Dec Vol. 20 Issue 6 Pg. 1510-7 ISSN: 1107-0625 [Print] Cyprus
• PMID: 26854448 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• ErbB Receptors

Topics

• Antibodies, Monoclonal (therapeutic use)
• Chemoradiotherapy
• Combined Modality Therapy
• ErbB Receptors (antagonists & inhibitors)
• Humans
• Lymphatic Metastasis
• Nasopharyngeal Neoplasms (mortality, therapy)
• Publication Bias